Fever of Unknown Origin
16
1
2
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 16 trials
100.0%
+13.5% vs benchmark
6%
1 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (16)
Fever of Unknown Origin (FUO) in Elderly Patients
The Investigators Will Evaluate the Diagnostic Performance of [18F]-AlF-FAPI-74 PET/CT in Inflammatory Disorders and Compare it With the Current Gold Standard for Inflammation, FDG PET/CT, in Three Patient Cohort: Patients Presenting With Fever of Unknown Origin, IgG4-RD and AxSpA.
Utility of 18F-FDG PET/CT for Suspected Infection in the Inpatient Setting: a Single Centre Retrospective Cohort Study
Primary Care-Hospital Embedding: a Prospective, Multicentric, Observational Study
68Ga Citrate PET/MRI for Evaluation of Fever of Unknown Origin (FUO)
Fever of Unknown Orgin Registry in Internal Medicine Unit and Infectious Disease Units
PLACE OF THE 18F-FDG-PET/CT IN THE DIAGNOSTIC WORKUP IN PATIENTS WITH CLASSICAL FEVER OF UNKNOWN ORIGIN (FUO)
PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases
Causes of FUO in Infants and Children
Evaluation of Diagnosis of Fever and Biologic Inflammatory Syndrome of Unknown Origin
A Two-step Method Apparently Improved the Physicians' Level of Diagnosis Decision-making for Adult Patients With FUO
Clinical Research for the Diagnosis of Tick-borne Diseases in Patients With Unexplained Acute Fever
Influence of Compound Qingre Granule on the Inflammatory Markers in Patient of FUO With Excess-heat Syndrome
Rapid Viral Diagnostics in Adults to Reduce Antimicrobial Consumption and Duration of Hospitalization
Granulocyte Transfusions in Hematological Patients With Febrile Neutropenia
PET CT in Suspected CIED Infection, a Pilot Study - PET Guidance I